Grifols, S.A. (GRFS)
UndervaluedFundamental
76
मूल्य
$7.31
मार्केट कैप
$4.98B
भाग 1 · कंपनी का मूल्य कितना है
अवलोकन
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services. It also offers biological products, including albumin, albumin-derived products, immunoglobulins, thrombin, other proteins, and intermediate plasma products to pharma and biotech companies for biopharma use; and whole blood, blood components, processed plasma, and clinical samples to life-science research and in-vitro diagnostic companies for diagnostic use. In addition, the company provides healthcare solutions for hospitals, such as intravenous solutions to maintain or restore fluids and electrolyte balance in patients; high-tech solutions to automate hospital processes; clinical nutrition to deliver nutrition and medication; and medical devices comprising instrumentation and disposable materials for various hospital services, which include interventional neuroradiology, hemodynamics, urology, anesthesiology and cardiovascular surgery, as well as manufacturing services to third parties and research activities. Further, it is involved in engineering services; packaging, labelling, storage, distribution, manufacturing, and development of pharmaceutical products; import, export, and commercialization activities; travel agency services; reinsurance of insurance policies; support services; law business; and consultation, administration, and financing services. The company was founded in 1909 and is headquartered in Barcelona, Spain.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
Generated on 18 सितंबर 2026 with claude-haiku-4-5 — shared with all users
A smaller US fractionator with its own donation centers whose immunoglobulin Asceniv competes for the same immunodeficiency patients and the same US plasma donors.
Its non-plasma antibody Vyvgart treats myasthenia gravis and CIDP, the neurological indications that account for a large share of Grifols' immunoglobulin revenue.
The largest plasma fractionator worldwide, it collects donor plasma in the same US centers and sells rival immunoglobulins and the alpha-1 therapy Respreeza against Grifols' Gamunex and Prolastin.
Through its BioLife donation network and its plasma-derived business, it sells a 10% liquid immunoglobulin and the alpha-1 products Aralast and Glassia to the same hospitals and specialty pharmacies Grifols supplies.
A privately held Swiss fractionator that runs its own US plasma centers and markets 5% and 10% liquid immunoglobulins competing head-on with Flebogamma and Xembify.
An Italian private plasma company selling immunoglobulins, albumin and hyperimmunes in Europe and the United States, the same product range and the same territories as Grifols' Biopharma division.
बैलेंस शीट और तरलता
राजस्व
$2.01B
अंतिम प्रकाशित तिमाही तक के पिछले 12 महीने — प्रति शेयर मेट्रिक्स से अनुमानित
शुद्ध आय
$172M
अंतिम प्रकाशित तिमाही तक के पिछले 12 महीने — प्रति शेयर मेट्रिक्स से अनुमानित
Free Cash Flow
$573M
कुल इक्विटी
$1.20B
कुल देनदारियाँ
$9.36B
Current Ratio
2.37
Interest Coverage
-
Debt/EBITDA
5.69
Earnings Per Share
राजस्व और शुद्ध आय
Free Cash Flow
आय विवरण
ऐतिहासिक विवरण
समय के साथ मार्जिन
समय के साथ ऋण
ऋण कितना भारी है
वृद्धि तालिका
वृद्धि — राजस्व
Fair Value अनुमान
Fair Value
$12.35
वर्तमान मूल्य
$7.31
Margin of Safety
+40.8%
Fair Value सीमा
$8.03 - $16.67
इस्तेमाल किए गए valuation methods के बीच का फैलाव, कोई सांख्यिकीय रूप से calibrated confidence interval नहीं।
अनुमान विधियाँ
मूल्यांकन मेट्रिक्स
P/E Ratio
10.99
ROE
6.9%
P/B Ratio
0.90
P/FCF
3.29
Gross Margin
37.0%
ROIC
8.8%
लाभप्रदता Radar
मूल्य सृजन (प्रतिस्पर्धी बढ़त)
ROIC
8.8%
WACC
3.6%
ROIC − WACC
+5.2 pp
ROIC पूंजी की लागत से अधिक है — कंपनी शेयरधारकों के लिए मूल्य सृजित कर रही है।
Fundamental विश्लेषण मानदंड
पास (16)
- ROIC 8.8%
- Gross Margin 37.0%
- P/FCF 3.29
- P/B Ratio 0.90
- Operating Margin 16.2%
- Positive Free Cash Flow
- Current Ratio
- Debt/EBITDA
- Price below Graham Number
- DCF valuation (Undervalued)
- ROE 8.4%
- Revenue Growth 5Y 7.1%
- Analyst Consensus 67% Buy
- Earnings Surprise avg 45.6%
- Earnings Quality (OCF/NI) 2.71
- Net Margin Trend 5.3% vs 2.2%
फेल (4)
- Price CAGR -7.72%
- Debt/Equity ratio
- CapEx intensity
- Piotroski F-Score 2/9
अनुपलब्ध (7)
- EPS data insufficient
- Dividend Payout NaN%
- Interest Coverage
- Return on Tangible Assets
- Low reliance on intangibles
- PEG Ratio (need PE > 0 and growth > 0)
- Share Dilution (missing shares data)
Piotroski F-Score
गंभीर वित्तीय चिंताएं
Earnings गुणवत्ता
उच्च गुणवत्ता: earnings नकदी द्वारा समर्थित
शेयर Dilution
शेयर वापस खरीद रही है। शेयरधारक अनुकूल
संस्थागत होल्डिंग
प्रशासन
कार्यकारी टीम
| नाम | पद | आयु |
|---|---|---|
| Mr. Jose Ignacio Abia Buenache | CEO & Director | 57 |
| Mr. Rahul Srinivasan | Chief Financial Officer | 48 |
| Mr. Lluis Pons Gomez | Senior Vice President of Strategy & COO Office | 41 |
| Daniel Segarra | Head of Investor Relations & Sustainability and Vice President | - |
| Mr. David Ian Bell | Chief Corporate Affairs & Legal Officer | 71 |
| Mr. Enrique de la Torre | Chief Compliance Officer | 52 |
| Ms. Montse Ribas | Chief Communications and Reputation Officer | 56 |
| Mr. Camille Alpi | Chief Human Resources & Talent Officer | 44 |
| Mr. Vicente Blanquer Torre | Chief Quality Officer | 64 |
| Mr. Ignacio Ramal Subira | Chief Internal Audit & Enterprise Risk Manager | 57 |
भाग 2 · कीमत और खरीदने का समय
यह हिस्सा यह नहीं बताता कि कंपनी अच्छी है या नहीं: यह तय करने में मदद करता है कि उसे कब खरीदें, जब फंडामेंटल आपको आश्वस्त कर चुके हों। इसमें: तकनीकी विश्लेषण, संभावना, ऐतिहासिक गिरावट, गामा एक्सपोज़र।
Latest News
Recent headlines for GRFS, sourced from Markets Gazette.